US5583153A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of taxol in the treatment of rheumatoid arthritis
Assignee: University of California
•
Filing: 1994-10-06
•
Granted: 1996-12-10
•
Expires: 2014-10-06
Abstract
Abstract An improved method of suppression of a progressive, inflammatory, autoimmune arthritis in a mammal involves the use of the drug Taxol. In general, such a method comprises administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion. The use of Taxol can be combined with the use of other antiarthritic drugs, such as the angiogenesis inhibitor AGM-1470, to produce a greater therapeutic effect than with either Taxol or the other antiarthritic drug alone.
Inventors
- 👤 Ernest Brahn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61K45/00; A61K45/06; A61K47/00; A61K47/44
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
59 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion.
Claim 2
Independent Claim
59 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the mammal is a rat and the arthritis is collagen-induced arthritis.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the mammal is a human being and the arthritis is rheumatoid arthritis.
Claim 5
Dependent Claim
24 words
The method of claim 1 wherein the pharmacologically acceptable carrier is a 1: 1 dilution of ethanol and cremophor EL, further diluted with saline.
Claim 6
Dependent Claim
32 words
The method of claim 1 wherein the dose sufficient to suppress at least one symptom of arthritis is from about 7.5 mg/kg body weight to about 10 mg/kg body weight of Taxol.
Claim 7
Dependent Claim
32 words
The method of claim 1 wherein the dose sufficient to suppress at least one symptom of arthritis is from about 0.075 mg/kg body weight to about 0.1 mg/kg body weight of Taxol.
Claim 8
Dependent Claim
32 words
The method of claim 1 wherein the dose sufficient to suppress at least one symptom of arthritis is from about 0.75 mg/kg body weight to about 1.0 mg/kg body weight of Taxol.
Claim 9
Dependent Claim
63 words
The method of claim 1 further comprising administering to the mammal an antiarthritic drug other than Taxol selected from the group consisting of a nonsteroidal antiinflammatory agent, an organic gold derivative, D-penicillamine, a 4-aminoquinoline, azathioprine, methotrexate, cyclosporin, an angiogenesis inhibitor, a monoclonal antibody to T cells, a monoclonal antibody to an adhesion molecule, and a monoclonal antibody to a cytokine or growth factor.
Claim 10
Dependent Claim
18 words
The method of claim 8 wherein the antiarthritic drug other than Taxol is the angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagillol.
Claim 11
Independent Claim
118 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising: (a) administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion; and (b) administering to the mammal the angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagillol in a dose sufficient to suppress at least one symptom of arthritis; the administration of both Taxol and ,AGM-1470 producing a greater degree of suppression of at least one symptom of arthritis than does the administration of the equivalent dose of either Taxol or O-(chloroacetylcarbamoyl) fumagillol alone.
Claim 12
Independent Claim
118 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising: (a) administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion; and (b) administering to the mammal the angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagillol in a dose sufficient to suppress at least one symptom of arthritis; the administration of both Taxol and ,AGM-1470 producing a greater degree of suppression of at least one symptom of arthritis than does the administration of the equivalent dose of either Taxol or O-(chloroacetylcarbamoyl) fumagillol alone.
Claim 13
Independent Claim
63 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising administering to a mammal having or susceptible to arthritis a Taxol derivative in a pharmacologically acceptable carrier capable of solubilizing the Taxol derivative in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion.
Claim 14
Independent Claim
63 words
A method for suppression of a progressive, inflammatory, autoimmune arthritis in a mammal comprising administering to a mammal having or susceptible to arthritis a Taxol derivative in a pharmacologically acceptable carrier capable of solubilizing the Taxol derivative in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion.
Claim 15
Dependent Claim
17 words
The method of claim 11 wherein the mammal is a rat and the arthritis is collagen-induced arthritis.
Claim 16
Dependent Claim
18 words
The method of claim 11 wherein the mammal is a human being and the arthritis is rheumatoid arthritis.
Claim 17
Dependent Claim
65 words
The method of claim 11 further comprising administering to the mammal an antiarthritic drug other than the Taxol derivative selected from the group consisting of a nonsteroidal antiinflammatory agent, an organic gold derivative, D-penicillamine, a 4-aminoquinoline, azathioprine, methotrexate, cyclosporin, an angiogenesis inhibitor, a monoclonal antibody to T cells, a monoclonal antibody to an adhesion molecule, and a monoclonal antibody to a cytokine or growth factor.
Claim 18
Dependent Claim
20 words
The method of claim 14 wherein the antiarthritic drug other than the Taxol derivative is the angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagillol.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-12-10 | 2000-06-10 | 2000-12-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-12-10 | 2004-06-10 | 2004-12-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-12-10 | 2008-06-10 | 2008-12-10 | $7700.00 | Window Closed / Lapsed |